Moderna recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent ...

Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever received at the company. The 16.4% increase—at grant value—came ...

US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to Moderna Inc., people familiar with the matter said. The review is part of a ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against firms that kick off shortened trading week with impressive gains. The stock market kicked off the ...

HHS cites need for review due to 'oversight' issues CDC states low risk of H5 bird flu to public Moderna's shares drop 5.5% Feb 26 (Reuters) - U.S. health officials are reevaluating a $590 million ...

Investors with a lot of money to spend have taken a bullish stance on Moderna MRNA. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a wider-than-expected fourth-quarter loss and offered soft guidance for 2025, offsetting ...

Meanwhile, despite a downgrade from Barclays, Moderna jumped over 8% on Tuesday, mainly due to management’s comment on prioritizing 10 high-value programs with possible approval over the next ...

Trump Administration Weighs Pulling Funding for Moderna Bird Flu Vaccine, Bloomberg News Reports (Reuters) - U.S. health officials are reevaluating a $590 million contract that was awarded to ...

Friday marked the worst day of the year for the stock market as the Dow lost 748.63 points, however, pharmaceutical companies stood out as a glaring exception, with both Pfizer and Moderna stocks ...

Shares of Moderna (MRNA), Pfizer (PFE) and Novavax (NVAX) all gained Friday, a broadly downbeat session that saw the S&P 500 slide 1.7%. Moderna was the biggest gainer on the benchmark index ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...